One of the biggest remaining catalysts for the entire cannabidiol (CBD) market in the US may see some movement later this year, according to one executive.

In her company’s Q2 operating results release on Wednesday (August 14), Deanie Elsner, CEO of Charlotte’s Web Holdings (TSX:CWEB,OTCQX:CWBHF), said she is expecting to see a framework for regulations in the US later this year.

Elsner said her company is preparing for the possibility that the US Food and Drug Administration (FDA) will move forward with clear regulations and guidance for the CBD market. She estimates that this may come in mid to late fall of this year.

“In the United States we are cautiously optimistic that the FDA is moving in the right direction and we believe they are committed to finding a positive path forward for the industry,” Elsner said during a conference call on Wednesday.

Following the legalization of hemp and its derivatives thanks to the passing of the farm bill, the FDA has expressed an interest in setting up a regulatory framework for CBD items used as dietary supplements.

Despite the lack of clarity from the regulator, the CBD market in the US has seen an explosion in interest and demand from consumers.

“While the farm bill unlocked the door for category availability, the FDA now has the opportunity to expand availability of hemp CBD products across more distribution points to benefit more consumers,” Elsner said during the call.

The executive was appointed as the new leader of the CBD manufacturer in April, having served previously as president of the US snacks division with Kellogg Company (NYSE:K).

Elsner explained that retail partners with massive store networks across the US will not get ahead of the FDA in terms of the product sales.

“Which is why the FDA really needs to be aware that in order for the industry to move forward they’ve got to set the regulatory down,” she said.

Q2 results show progress in market availability and revenues

During its most recent quarter, the Boulder, Colorado-based manufacturer of CBD products reported revenues of US$25 million compared to US$21.7 million during the previous quarter.

The company reported total net income of US$2.2 million for the period, which represents earnings per share of US$0.02.

Elsner explained that the company has seen healthy growth in terms of its products becoming available at national retailers and smaller regional stores. Charlotte’s Web-branded CBD products are now available in 8,000 stores across the US.

The company touts its brand as a premium offering that consumers will seek out compared to other products. However, Elsner said she is expecting to see a natural price compression due to the high volume of competitors offering cheaper CBD products.

The executive explained that the company is not considering dropping its own prices in the face of the emergence of these low-cost competitors.

Elsner said this decision was made since the company has not seen a significant enough impact from the entry of competition with cheaper products.

Fellow CBD producer CV Sciences (OTCQB:CVSIshared similar projections about the expansion of lower-cost competition in this sector. During a recent quarterly update, CEO Joseph Dowling warned investors the company will be facing murky upcoming quarters from increased competition in the CBD space.

Shares of Charlotte’s Web opened Wednesday at C$25.51. As of 2:05 p.m. EDT, the company had fallen over 10 percent from its previous close, coming in at C$25.71.

In the company’s conference call, Cory Pala, director of investor relations, attributed the drop in the share price to the struggles of the Dow Jones Industrial Average (INDEXDJX:.DJI).

According to analyst aggregator site TipRanks, Michael Lavery, an analyst with Piper Jaffray, kicked off his coverage of the firm this week by issuing a “buy” rating and assigning a C$25 price target to the company.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less